Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anterior cingulate cortex

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Anterior cingulate cortex. Displaying page 1 of 1.
    EudraCT Number: 2018-001212-30 Sponsor Protocol Number: ECEP-BPD Start Date*: 2018-09-18
    Sponsor Name:Central Institute of Mental Health, represented by commercial and administrative Director
    Full Title: A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002011-61 Sponsor Protocol Number: 77267 Start Date*: 2021-08-13
    Sponsor Name:Academisch ziekenhuis Maastricht
    Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
    Medical condition: 22q11.2 deletion syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003750-89 Sponsor Protocol Number: KKS-186 Start Date*: 2013-02-14
    Sponsor Name:Philipps-University Marburg
    Full Title: A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy
    Medical condition: high-functioning autism spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F 84.1)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10021737 Infantile autism LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011172-30 Sponsor Protocol Number: A9951007 Start Date*: 2009-08-10
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S...
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004120-12 Sponsor Protocol Number: AAB-001-202 Start Date*: 2005-05-27
    Sponsor Name:Elan Pharma Ltd
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN116727) in Pa...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    5.1 10001897 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004528-19 Sponsor Protocol Number: I001PS0807_1 Start Date*: 2008-01-11
    Sponsor Name:University of Wuerzburg
    Full Title: Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®
    Medical condition: schizophrenia (295.10, 295.20, 295.30, 295.90 according to Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003957-16 Sponsor Protocol Number: ZonMw80-83600-98-3074 Start Date*: 2016-08-30
    Sponsor Name:University Medical Centre Groningen
    Full Title: A randomised controlled trial of oral S-ketamine as add-on medication for patients with treatment-resistant major depressive disorder
    Medical condition: Treatment resistant major depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003336-12 Sponsor Protocol Number: FatherTrials2015 Start Date*: 2016-03-23
    Sponsor Name:Universiteit Leiden
    Full Title: Father Trials: Hormonal Experiments on Prenatal and Postnatal Parenting
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10047146 Vasopressin LLT
    18.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000103-20 Sponsor Protocol Number: 202000638 Start Date*: 2021-07-15
    Sponsor Name:University Medical Center Groningen
    Full Title: An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa
    Medical condition: Genetic Epidermolysis Bullosa
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002534-16 Sponsor Protocol Number: FSJD-INNOVA-2020 Start Date*: 2021-10-15
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: 12-month randomized, double-blind, placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects of low-dose Naltrexone in patients with...
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001839-23 Sponsor Protocol Number: 14137A Start Date*: 2012-05-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted fro...
    Medical condition: Cognitive dysfunction Major depressive disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001877-13 Sponsor Protocol Number: TMT107235 Start Date*: 2006-08-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator par...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004025-20 Sponsor Protocol Number: TMT110684 Start Date*: 2007-10-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in partic...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004740-30 Sponsor Protocol Number: PHRCN2018 Start Date*: 2021-09-15
    Sponsor Name:Centre Hospitalier Le Vinatier
    Full Title: Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.
    Medical condition: CARAMEL is an exploratory phase-2 study conducted in subjects with AUD (alcohol use disorder) and current heavy drinking level, aiming to confirm the different properties of CBD observed in animal ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001590 Alcohol addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003079-20 Sponsor Protocol Number: 18F-AV-45-C02 Start Date*: 2013-01-10
    Sponsor Name:AVID RADIOPHARMACEUTICALS, INC.
    Full Title: Evaluation of florbetapir (18F) PET in subjects participating in the IRCCSFBF protocol
    Medical condition: Alzheimer's disease and other neurodegenerative diseases, as for example Dementia with Lewy bodies, Parkinson Dementia, Vascular Dementia and Tau Protein associated Dementia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020370-42 Sponsor Protocol Number: NN25310 Start Date*: 2011-01-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000784-23 Sponsor Protocol Number: KKS-276 Start Date*: 2020-11-17
    Sponsor Name:Philipps-Universität Marburg
    Full Title: The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect)
    Medical condition: To unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressiv...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    21.1 10037175 - Psychiatric disorders 10081270 Major depressive disorder LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020696-23 Sponsor Protocol Number: NN25307 Start Date*: 2011-03-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:11:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA